Skip to main content
Premium Trial:

Request an Annual Quote

Parse Biosciences Closes $41.5M Series B Round

NEW YORK – Single-cell genomics company Parse Biosciences said Tuesday it has closed a $41.5 million Series B financing round.

The Seattle-based firm said it will use the funds to ramp up the commercialization of its Evercode Whole Transcriptome products and to expand its product portfolio to support multiomics.

Marshall Wace and Janus Henderson Investors co-led this round, joined by Soleus Capital, Logos Capital, and Bioeconomy Capital, bringing Parse's total funding to date to over $50 million.

A University of Washington spinout, Parse has been commercializing split-pool ligation-based transcriptome sequencing, a single-cell RNA-seq technology that chemically fixes and immobilizes cells. With the funds raised in this round, it will expand its Evercode product line into immune profiling, chromatin profiling, high-throughput CRISPR screens, targeted gene panels, and enhanced sensitivity, "enabling researchers to elevate single cell multiomic measurements to unprecedented scale," the company said.

"Understanding the transcriptome is pivotal, but our expansion into multiomics is a natural progression," said Alex Rosenberg, CEO and cofounder of Parse. "We're excited to begin expanding our product portfolio, starting later this year."

Last January, Parse raised $7 million in Series A financing.